Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01309737 · ClinicalTrials.gov registry record · Phase 3
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 960
- Enrollment target
NCT01309737 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 960 participants.
The verdict
NCT01309737, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 960 participants
- Enrollment target
Study Summary
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis. This one-year study will also evaluate the safety and tolerability of CP-690,550 versus placebo.
Interventions
- DRUG CP-690,550
- DRUG Placebo/CP-690,550
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 960 participants |
| Start Date | 2011-03 |
| Est. Completion | 2013-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01309737
The ClinicalTrials.gov registry entry for NCT01309737 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 960 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CP-690,550 is the first listed.
NCT01309737 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01309737 about?
NCT01309737 is a clinical study titled "A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis". The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis. This one-year study will also evaluate the safety and tolerability of CP-690,550 versus placebo.
What is the current status of trial NCT01309737?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 960 participants. The study started on 2011-03. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01309737?
The interventions under investigation include: CP-690,550 (DRUG), Placebo/CP-690,550 (DRUG).
Who is sponsoring clinical trial NCT01309737?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.